Sampo plc: Disclosure Under Chapter 9 Section 5 of the Securities Market Act (BlackRock, Inc.)
SAMPO PLC STOCK EXCHANGE RELEASE 16 April 2021 at 3:30 pm
Disclosure Under Chapter 9 Section 5 of the Securities Market Act (BlackRock, Inc.)
Sampo plc (business code 0142213-3) has received a disclosure under Chapter 9, Section 5 of the Securities Markets Act, according to which the total number of voting rights attached to Sampo A shares (ISIN: FI009003305) owned directly, indirectly or through financial instruments by BlackRock, Inc. (USA tax ID 32-0174421) and its funds increased on 15 April 2021 above five (5) per cent of Sampo plc’s total voting rights.
In addition, the disclosure obligation arose due to the number of Sampo A shares owned directly or indirectly by BlackRock, Inc. and its funds increasing above 5 per cent.
Sampo's share capital comprises 555,351,850 shares, of which 554,151,850 are A shares and 1,200,000 are B shares. Each A share entitles its holder to one (1) vote and each B share to five (5) votes. Thus, the total number of votes is 560,151,850.
Total positions of BlackRock, Inc and its funds subject to the notification:
% of shares and voting rights (total of A) | % of shares and voting rights through financial instruments (total of B) | Total of both in % (A+B) | |
Resulting situation on the date on which threshold was crossed or reached | 5.01% shares 4.97% voting rights | 0.06% shares 0.06% voting rights | 5.07% shares 5.03% voting rights |
Positions of previous notification (if applicable) | 4.93% shares Below 5% voting rights | 0.12% shares Below 5% voting rights | 5.04% shares Below 5% voting rights |
Notified details of the resulting situation on the date on which the threshold was crossed:
A: Shares and voting rights:
Class/type of shares ISIN code | Number of shares and voting rights | % of shares and voting rights | ||
Direct (SMA 9:5) | Indirect (SMA 9:6 and 9:7) | Direct (SMA 9:5) | Indirect (SMA 9:6 and 9:7) | |
FI0009003305 | 27,835,890 shares 27,835,890 voting rights | 5.01% shares 4.97% voting rights | ||
SUBTOTAL A | 27,835,890 shares 27,835,890 voting rights | 5.01% shares 4.97% voting rights |
B: Financial instruments according to SMA 9:6a:
Type of financial instrument | Expiration date | Exercise/ Conversion Period | Physical or cash settlement | Number of shares and voting rights | % of shares and voting rights |
American Depository Receipt (US79588J1025) | N/A | N/A | Physical | 267,491 shares 267,491 voting rights | 0.05% shares 0.05% voting rights |
Securities Lent | N/A | N/A | Physical | 52,022 shares 52,022 voting rights | 0.01% shares 0.01% voting rights |
CFD | N/A | N/A | Cash | 953 shares 953 voting rights | 0.00% shares 0.00% voting rights |
SUBTOTAL B | 320,466 shares 320,466 voting rights | 0.06% shares 0.06% voting rights |
SAMPO PLC
Jarmo Salonen
Head of Investor Relations and Group Communications
tel. +358 10 516 0030
Distribution:
Nasdaq Helsinki
London stock exchange
The principal media
Financial Supervisory Authority
www.sampo.com
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
CDR-Life to Present Tumor Targeting Capabilities of M-gager® Platform at the TCR-Based Therapies for Solid Tumors Summit23.4.2024 11:00:00 CEST | Press release
ZÜRICH, Switzerland, April 23, 2024 (GLOBE NEWSWIRE) -- CDR-Life Inc. today announced a presentation on its proprietary antibody-major histocompatibility complex (MHC) technology for the development of highly specific T-cell engagers (TCE) at the TCR-Based Therapies for Solid Tumors Summit, occurring April 23-25 in Boston, Massachusetts. The presentation will discuss how antibodies targeting tumor peptides on the MHC enable T-cells access to an untapped reservoir of intracellular tumor antigens and will highlight the M-gager® technology’s ability to leverage the potency, versatility and manufacturability of antibodies to revolutionize cancer immunotherapy. Presentation Details Title: Unlocking Tumor Eradication with Antibody-MHC T Cell Engagers Presenter: Leonardo Borras, Chief Scientific Officer Date: April 23, 2024 About CDR-Life CDR-Life is developing powerful T-cell engagers (TCE) to eradicate hard-to-treat solid tumors. Our integrated antibody-based TCE platform unlocks access to
Planlagt suspension i Sparinvest SICAV23.4.2024 10:54:57 CEST | pressemeddelelse
København, April 23, 2024 (GLOBE NEWSWIRE) -- Det skal oplyses, at der grundet lokale børslukkedage i underliggende markeder vil være suspension af nedenstående afdelinger onsdag d. 1 maj 2024. Fund nameISINOrder book codeEquitas EUR RLU0362354549SSIEEURREthical Global Value EUR RLU0362355355SSIEGVEURREuropean Value EUR RLU0264920413SSIEUVEURRGlobal Value EUR RLU0138501191SSIGVEURR Eventuelle spørgsmål vedrørende denne meddelelse kan rettes til npa.pm@nykredit eller Christian Rye Holm, CRH@nykredit.dk. Med venlig hilsen ID-Sparinvest, Filial af Sparinvest S.A, Luxembourg Dirk Schulze
Planlagt suspension i Investeringsforeningen Sparinvest23.4.2024 10:52:33 CEST | pressemeddelelse
Det skal oplyses, at der grundet lokale børslukkedage i underliggende markeder vil være suspension af nedenstående afdelinger onsdag d. 1 maj 2024. Fund nameISINOrder book codeMix Aktier KL ADK0010014778SPIMAKLAValue Aktier KL ADK0010079631SPIVAKLAValue Europa KL ADK0060032571SPIVEUKLAValue Emerging Markets KL ADK0010304856SPIVEMKLABæredygtige Aktier Akk. KL ADK0060012896SPIBDAAKKKLAINDEX Dow Jones Sustainability World KLDK0010297464SPIDJWKLINDEX Emerging Markets KLDK0060300762SPIEMIKLINDEX Europa Growth KLDK0010297548SPIEUGKLINDEX Europa Small Cap KLDK0010297621SPIEUCKLINDEX Europa Value KLDK0010297704SPIEUVKLBæredygtige Aktier KL ADK0061294048SPIBDAGlobale Fokusaktier KL ADK0061293826SPIGFAMix Maksimum Risiko KL ADK0061551892SPIMMRIABæredygtige Value Aktier KL ADK0061551546SPIBDVAAMix Lav Risiko KL ADK0060623189SPIMLRKLAMix Mellem Risiko KL ADK0060623262SPIMMRKLAMix Høj Risiko KL ADK0060623346SPIMHRKLAMix Minimum Risiko KL ADK0060914901SPIMIXMINRISKKLA Eventuelle spørgsmål vedrørende
Delårsrapport for perioden 1. januar - 31. marts 202423.4.2024 10:47:40 CEST | pressemeddelelse
Bestyrelsen for Tivoli A/S har den 23. april 2024 behandlet og godkendt delårsrapporten for perioden 1. januar - 31. marts 2024. Tivoli åbnede sommersæsonen 22. marts, hvilket er tidligere end sidste år hvor sæsonen åbnede 31. marts. Dette påvirker resultatet for perioden som i hovedtræk er: En nettoomsætning på 90,4 mio. kr. mod 61,8 mio. kr. sidste år (+46%).Et resultat før af- og nedskrivninger (EBITDA) på -84,2 mio. kr. mod -96,7 mio. kr. sidste år.Et resultat før skat på -112,4 mio. kr. mod -126,1 mio. kr. sidste år.Et besøgstal på 221.000 mod 47.000 sidste år (+470%). ”Tivoli fortsætter den positive udvikling, vi så i 2023. Første kvartal 2024 tegner sig for et resultat svarende til det forventede, med bedre gæstetal og økonomisk resultat, end samme periode i 2023. Vi går ind i sommersæsonen med optimisme og en lang række attraktive tilbud til Tivolis gæster, som bl.a. kan se frem til en sommer med et overordentlig stærkt kulturprogram.” udtaler adm. direktør, Susanne Mørch Koch
Interim Report for the period 1 January – 31 March 202423.4.2024 10:47:40 CEST | Press release
The Supervisory Board of Tivoli A/S has adopted the Interim Report for the period 1 January – 31 March 2024. Tivoli opened the summer season on 22 March, which is earlier than last year when the season opened 31 March. This affects the results for the period 1 January – 31 March 2024 in outline: A revenue of DKK 90.4 million compared to DKK 61.8 million last year (+46%).An EBITDA of DKK -84.2 million compared to DKK -96.7 million last year.A profit before tax of DKK -112.4 million compared to DKK -126.1 million last year.An attendance figure of 221,000 visitors compared to 47,000 last year (+470%). ”Tivoli continues the positive development we saw in 2023. The first quarter of 2024 is shaping up to a result equivalent to the expected, with better attendance figures and financial results than the same period in 2023. We enter the summer season with optimism and a wide range of attractive offers for Tivoli’s guests, who can look forward to a summer with a remarkably strong cultural progr